Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...
1d
Hosted on MSNDepression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in SeniorsFor older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...
In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...
They do this by blocking the action of an enzyme called dipeptidyl peptidase-4 (DPP-4). This enzyme breaks down hormones that reduce blood sugar levels. By interfering with this process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results